BioAdvance
Venture capitalConshohocken · Pre-Seed–Late Stage · 18 people tracked
Investment thesis
BioAdvance backs early-stage life-science companies in the U.S. Mid-Atlantic region with the potential to enhance human well-being and quality of life. Structured as an evergreen fund, it takes a long-term investment perspective and continues to grow and reinvest over time. Its portfolio companies span therapeutics, medical devices, diagnostics, and digital health, and collectively have attracted over $4.4 billion of external follow-on capital to support their growth.
Source: firm website, verified Aug 3, 2026.
Team · 18 people
from the firm's website & public directories
What they invest in
from 20 of 58 portfolio companiesBiotech ×16Healthtech ×7Medical Devices ×4Deep Tech ×1Digital Health ×1SaaS ×1
HQs:United States×22
Investments · 58 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 12022 · 12018 · 12017 · 22015 · 17 dated
BiotechNew York, US
Sergio Traversa(Executive Officer, Director)Charles Casamento(Director)Paul Kelly(Director)Maged Shenouda(Director)
Nurse retention platform designed to identify risk up to 12 months in advance.
HealthtechPhiladelphia, US
Joseph Kaupp(Executive Officer, Director)Sean O'Neill(Executive Officer, Director)Steven Powell(Director)Patrick Fitzgerald(Director)Sam Wilson(Executive Officer)
BoardAmy Gallagher(Director)
BiotechHummelstown, US
Stephen C. Rocamboli(Executive Officer, Director)Rifat Pamukcu(Director)Robert Towarnicki(Executive Officer, Director)Roger Sawhney(Director)
BoardTim Van Treuren(Director)John Fucci(Director)
HealthtechNew York, US
Steve Agular(Director)Sean Kearney(Director)Melissa P. Manice(Executive Officer, Director)Daniel Weinstein(Executive Officer, Director)
Concarlo Therapeutics develops cancer therapeutics that target CDK4/6-driven cell proliferation and CDK2-driven resistance, focusing on improving outcomes for cancer patients through novel approaches in p27 biology.
BiotechBrooklyn, US
LisaMarie Casey(President and Manager)Stacy Blain(Founder and CEO)
ENB Therapeutics develops oncology molecules that block the endothelin B receptor (ETBR) to improve immune-based cancer therapies.
BiotechHealthtechNew York, US
Fumitaka Mori(Director)Sumayah Jamal(President, Co-founder & Chief Scientific Officer)Albert Sokol(Executive Officer)Sandy Harm(Chief Operating Officer)Robert Schneider(Co-founder & Chair of Scientific Advisory Board)
BoardBarbara Schilberg(Director)
King Of Prussia, US
William Conlan(Executive Officer, Director)Mark McAdoo(Executive Officer, Director)David Tamburri(Director)Mike Kane(Director)
BiotechNew York, US
Nader Halim(Executive Officer, Director)Althea Stillman(Executive Officer, Director)
BoardJonathan Leff(Director)David Greenwald(Director)
BiotechCranbury, US
Wei Wang(Executive Officer, Director)Bo Liang(Executive Officer, Director)Houman Hemmati(Executive Officer, Director)John J Baldwin(Director)Tao Du(Director)
BoardQi Zhu(Director)
KaloCyte develops ErythroMer, a dried, shelf-stable artificial red blood cell for use in emergency and trauma care when stored blood is unavailable or in short supply.
BiotechDeep TechHealthtechMedical DevicesBaltimore, US
Allan Doctor(Co-Founder & CSO)inDipanjan Pan(Co-Founder, Chief Technical Officer)inPhilip Spinella(Co-Founder, Chief Medical Officer)inDaniel Getman(Director)Gregory Lanza(Director)
Keriton offers a software platform for neonatal and pediatric hospital settings that supports safe infant feeding practices, milk management (donor human milk, formula, and parental human milk), and family engagement through features like secure photo sharing, e-journaling, and clinician messaging.
BiotechDigital HealthHealthtechSaaSPhiladelphia, US
Vidur Shailendra Bhatnagar(Manager)
Gene therapy company; recently appointed Bethany Mancilla as Chief Business Officer.
BiotechPhiladelphia, US
Shariff S. Bayoumy(Executive Officer)Brett A. Tounge(Executive Officer, Director)Lawrence C. Kuo(Executive Officer)Michael Serrano-Wu(Director)
BoardBarbara Schilberg(Director)
BiotechSpring House, US
Harry Arader(Director)Rifat Pamukcu(Executive Officer, Director)
BiotechWayne, US
Roy Levitt(Executive Officer, Director)Stephen Tullman(Executive Officer, Director)Paul Barone(Executive Officer, Director)Brian Lortie(Executive Officer, Director)Douglas Gessl(Executive Officer)
BiotechBryn Mawr, US
Martin D. Phillips(Executive Officer, Director)Nicholas W. Lukacs(Director)Frank Marcoux(Director)Alan E. Casnoff(Director)
HealthtechPhiladelphia, US
Michael Zeidlhack(Executive Officer, Director)Marc Tobias(Executive Officer, Director)Naveen Muthu(Director)
New York, US
James Wyman(CFO and Director)Yogendra Jain(Director)Emanuele Musini(CEO and Director)
BiotechGreenwhich, US
Arthur Feldman(Director)Magdalene Cook(Executive Officer, Director)Wendy DiCicco(Ms. DiCicco is the Secretary and Treasurer of the Issuer.)Campbell Murray(Director)Edward J. Benz, Jr.(Director)Thomas Needham(Director)
Ribonova is a biopharmaceutical company discovering and developing novel small-molecule medicines for patients with serious rare diseases.
BiotechMedical Devices
BiotechPhiladelphia, US
Philip Ball(Executive Officer, Director)Damia Tormo Carulla(Director)Justin Vogel(Executive Officer, Director)Francisco Leon(Executive Officer, Director)Robert Goldstein(Director)
BoardPablo Cironi(Director)
Developing ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor combination for complicated urinary tract infections.
Malvern, US
Vesteck develops medical device technology in the cardiovascular/endovascular space.
HealthtechMedical DevicesWest Chester, US
John Edoga(Director)Rafferty Joseph(Executive Officer, Director)Edward Wulfman(Executive Officer)Kent Stalker(Principal Investigator)JOHN DIEDERICH(Director)THIERRY RICHARD(Director)
Vittoria Biotherapeutics is a clinical-stage company developing next-generation autologous CAR T-cell immunotherapies for oncology and immunology, built on its Senza5 platform that uses CD5 signaling modulation and a 5-day manufacturing process.
BiotechMedical Devices
Exits · 3
IPOs and acquisitions across the tracked portfolioImmunomeNASDAQ: IMNMPalvella TherapeuticsNASDAQ: PVLARelmada TherapeuticsNASDAQ: RLMD
Portfolio news
latest coverage across their companiesTolerance Bio · intelligence360.news · Jul 28, 2026
Frequently asked questions
- What stage does BioAdvance invest at?
- BioAdvance invests at the Pre-Seed, Seed, Series A, Late Stage stages.
- What is BioAdvance's typical check size?
- BioAdvance typically writes checks of $500K – $1.5M.
- What sectors does BioAdvance focus on?
- BioAdvance focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is BioAdvance located?
- BioAdvance is headquartered in Conshohocken, US.
- Does BioAdvance lead rounds?
- Yes, BioAdvance leads investment rounds.
Media · Podcasts & interviews
featuring the teamShahram Hejazi & Rick Jones of BioAdvance - 2020 Speaker Series - January 30th
Jefferson Innovation · Shahram Hejazi
Images
Similar investors
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Lumira Ventures is a North American life sciences venture capital firm that partners with mission-driven entrepreneurs to build companies developing and commercializing healthcare products for patients.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Foresite Capital is a multi-stage investment firm focused on healthcare and life sciences, backing companies across all stages of growth. It applies a data science-driven approach to invest in businesses leveraging biology and big data to transform healthcare.